Market accessCompany release

Amarin returns to small Q3 profit as Vazkepa launches privately paid in Poland

🇺🇸 Amarin Corp Plc\Uk (AMRN) · Wed 28 Oct 2026

Amarin posted a slim third-quarter 2026 net profit despite a 20% revenue fall, while partner Recordati began non-reimbursed sales of icosapent ethyl in Poland.

Amarin reported third-quarter 2026 results on 28 October, showing a small net profit even though revenue fell 20%. The company attributed the decline to price pressure from generic competition in the US.

Icosapent ethyl, marketed as Vascepa in the US and Vazkepa in Europe, is now sold in 22 countries. Eleven of those are in Europe, where Amarin's partner Recordati commercialises the product.

In October, Recordati launched Vazkepa in Poland on a private-pay basis, meaning patients pay without reimbursement. According to the company, Recordati is still pursuing pricing and reimbursement arrangements in other European markets.

Amarin also pointed to Phase 3 EMT2 findings presented at ESMO 2026. The investigator-led University of Leeds study tested Vascepa as an add-on treatment in colorectal cancer liver metastases. The summary available does not give the trial's results.

What it means for your team

  • Market-access teams should note that Poland is a private-pay launch: Vazkepa is available there without reimbursement, and reimbursement efforts continue in other European markets.
  • The European footprint of 11 countries, all through Recordati, shows access remains country-by-country and depends on national pricing and reimbursement decisions.
  • The EMT2 oncology data are investigator-led and were presented at a congress; they do not by themselves change the product's current labelled use.

Company's press release (SEC filing): Amarin Corp Plc\Uk ↗

Article written by VigiEye from the official source (Amarin Corp Plc\Uk). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →